Andrew Penrose has joined Polymer Laboratories as technical specialist in polymer characterisation. He has expertise in size exclusion chromatography, as well as experience of a wide variety of analytical techniques and methods of polymer characterisation. He also has an interest in electrically driven separation techniques, including those emerging for polymer characterisation.
Inovio, a Norwegian biotech company specialising in the development and use of electroporation-based drug delivery systems for in vivo delivery of genes and other biomolecules, has named David J. Pyrce as chief business officer. He will be responsible for strategy and business development and leading the firm's strategic partnering efforts.
Innate Pharma, a biopharmaceutical company developing novel anti-tumoural therapies, has appointed Dr Aziz Benzohra as director of clinical development. The appointment comes as Innate Pharma is about to move a second product into phase I of clinical development.
zuChem, the US supplier of glycochemicals and other specialised sugars for the pharmaceutical, food and nutraceutical industries, has appointed a number of senior advisors to help guide the company's strategy and research programmes. Dr Charles Bibart, who recently retired as group vice president, global supply for Pharmacia Corporation, joins the board of directors.
There are also three new members of the scientific advisory board: Dr David Ager, currently competence manager for DSM Fine Chemicals; Dr Ian Fotheringham, a biotransformation consultant and president of Edinburgh-based bioprocess development company Ingenza; and Dr David Dodds, most recently director of fermentation and biocatalysis development for Bristol-Myers Squibb.
De Novo Pharmaceuticals, the in silico drug design company based in Cambridge in the UK, has named Dr Bart Wuurman as its new ceo. Dr Mike Ashton becomes chairman, replacing Alan Goodman, who will stay on as board member.
Dr Wuurman joins De Novo from Antisoma, where he was director of business development.
NeuTec Pharma has appointed Dr Robert Nolan as a non-executive director. Dr Nolan has more than 30 years of experience in the pharmaceutical industry and has been director of global licensing at AstraZeneca since 1989. He currently manages major product licensing transactions worldwide.